Oncolytic Viruses Shown to Target and Kill Pancreatic Cancer Stem Cells

Oncolytic viruses quickly infect and kill cancer stem cells, which may provide a treatment for tumors that are resistant to conventional chemotherapy and radiation, particularly pancreatic cancer, according to new research. The findings are particularly significant since pancreatic cancer has a poor prognosis and is difficult to detect and treat at early stages.

Investigators led by Joyce Wong, MD, a surgical researcher with Memorial Sloan-Kettering Cancer Center (New York, NY, USA), examined whether they could use oncolytic viruses, which are naturally occurring viruses that have been genetically engineered to be safe and express tracking genes, as a possible therapy against pancreatic cancer stem cells. These stem cells are thought to cause disease recurrence and metastasis, even after therapy, and oncolytic viruses may offer a new treatment strategy.

“What we learned is that oncolytic viruses have been engineered to selectively target cancer cells and have a low toxicity profile in animal studies,” said Dr. Wong. “Targeting the cancer stem cell may enhance our ability to eradicate tumors and prevent future recurrence of disease.”

While much research has been performed on isolating the cancer stem cell from various hematologic cancers, this research was based on the presence or absence of specific cell surface markers. Numerous mechanisms of how these cancer stem cells resist chemotherapy and radiation have also been examined. However, up to now, there has not been any research assessing whether genetically modified viruses can target and kill pancreatic cancer stem cells.

Investigators tried to determine whether the viruses containing a marker gene that expresses green fluorescent protein could infect pancreatic cancer stem cells and ultimately kill the cancer stem cell. Their findings were promising and validated that viral activity was correlated with green fluorescent protein expression.

Dr. Wong added that future studies are needed to determine whether oncolytic virus administration in vivo will help eradicate tumors and prevent future disease recurrence, and that while these initial findings are encouraging, further study is necessary to see whether oncolytic viruses will be clinically beneficial as a therapy.

Dr. Wong presented the study’s findings at Digestive Disease Week 2011 (DDW) May 9, 2011, in Chicago (IL, USA). DDW is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Related Links:
Memorial Sloan-Kettering Cancer Center

Source : http://www.biotechdaily.com/?option=com_article&Itemid=294735250&cat=Therapeutics&ui=1960157264&vrf=2e5e5bfeac168ddcf9fcaffa762c5af6&end=%2520